CIS Bio to license tracer technology

July 13, 1994

French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new

French radiopharmaceuticaldeveloper CIS Bio International has licensed technology for developingtechnetium-based radiotracers to Nihon Medi-Physics of Japan.The deal, which was signed in May, covers a new process developedby CBI to obtain new technetium-labeled compounds. The agreementincludes rights for a nuclear cardiology agent that shows promisein imaging myocardial ischemia and infarction, according to thecompany.